

Time to define One Health approaches to tackling antimicrobial resistance

Patrick Musicha, Tracy Morse, Derek Cocker, Lawrence Mugisha, Christopher P. Jewell & Nicholas A. Feasey



Recent data re-affirm antimicrobial resistance (AMR) as a One Health problem, particularly in low- and middle-income countries. Transdisciplinary and intersectoral collaboration are required if we are to improve environmental hygiene, addressing both AMR and a range of aligned development challenges.

Antimicrobial resistance (AMR) has been described as “the quintessential One Health problem” and it is believed that any meaningful effort to ameliorate this global public health challenge will require transdisciplinary and intersectoral collaboration to improve health for humans, animals and the environment¹. There is not, however, enough evidence describing how antimicrobial resistant bacteria flow between different ecological compartments, or precisely what form One Health solutions to the problem of AMR should take. The complex and tightly correlated landscape of AMR transmission in the ecosystem means that results from studies powered to examine one particular aspect are likely affected, or even biased, by dependencies on other aspects. This lack of clarity poses serious challenges for selecting and balancing interventions to control AMR, especially as strong, potentially competing cases can be made to focus resources on antimicrobial stewardship and/or infection, prevention and control (IPC) practices in health care facilities on one hand, and water, sanitation and hygiene (WASH) practices in community settings on the other hand. Filling this evidence gap has become more pressing given that several recent studies, mostly from high-income settings, have shown limited evidence of a role for animal and environmental reservoirs in the human acquisition of key AMR pathogens.

Limited evidence for AMR as a One Health problem in high-income countries

A study of extended spectrum beta-lactamase (ESBL) producing *E. coli* by Public Health England (now UK Health Security Agency) compared isolates from human faeces, sewage, farm slurry, and retail foodstuffs to human bloodstream infection (BSI) isolates and found little overlap between non-human reservoirs and isolates from invasive human disease². Similarly, a genomic surveillance of *E. coli* in the UK found distinct lineages and mobile genetic elements of *E. coli* between human BSI and livestock samples³. A recent study of *Klebsiella pneumoniae* from a wide range of clinical, community, animal and environmental settings in Italy, described by the authors as “a hotspot for hospital-acquired carbapenem non-susceptible *Klebsiella*”, found no genotypic or phenotypic evidence for non-susceptibility to carbapenems outside the clinical environment⁴. In these studies, a lack of relatedness

between bacterial isolates found in human infection samples and isolates from other ecological sources may not equate to a lack of transmission between ecological compartments. The sampling strategies employed including sampling animals from closed farms alongside unlinked humans from a large geographical area, may have influenced the ability to detect significant or potential transmission events⁵.

Emerging data re-affirm AMR is a One Health problem in LMICs

On the other hand, some studies have shown evidence for a strong association between poor environmental health infrastructure and AMR, particularly affecting the most vulnerable populations in the world⁶. The Drivers of Resistance in Uganda and Malawi (DRUM) study, collected demographic, geospatial, clinical, animal husbandry and environmental health (including WASH infrastructure and practice) data from households in urban, peri-urban and rural settings in Uganda and Malawi⁷. Longitudinal human, animal and environmental sampling at each household was used to isolate ESBL *E. coli* and ESBL *K. pneumoniae*. Multivariable models illustrated that human ESBL-producing *E. coli* colonisation was associated with the wet season and close animal interaction, and that without adequate efforts to improve environmental health, ESBL-producing Enterobacteriaceae transmission is likely to persist in these settings^{8,9}.

E. coli is a highly diverse species, and the resolution offered by whole genome sequencing (WGS) reveals that sub-groups of *E. coli*, even at the level of discrimination offered by multi-locus sequence typing are generally distinct in different ecological sources. Despite this, there is flow of antimicrobial resistant strains or AMR genes between one health compartments. This is particularly evident in sub-Saharan Africa (sSA), where analysis of *E. coli* genomes from the UrbanZoo study in Kenya demonstrated that although transmission of the general *E. coli* population is often within host species¹⁰, there is significant flux of accessory genes on mobile genetic elements (MGE), especially AMR genes, between humans and animals^{11,12}. Sharing of the accessory genomes across different sources was also observed among *K. pneumoniae* isolates from clinical, environmental, and animal sources in Ghana, an indication of transmission of *K. pneumoniae* between the different compartments¹³.

In Malawi and Uganda, comparison of *E. coli* genomes revealed high diversity of *E. coli*, MGE and ESBL genes that were distributed independent of ecological compartments¹⁴. Detailed lineage level SNP analysis of these genomes further indicated putative transmission events of ESBL-*E. coli* between humans, animals and the environment¹⁴. Outside sSA and Europe, evidence of phylogenetic intermixing and sharing of AMR genes between humans, animals and soil has been reported in Bangladesh¹⁵. Similarly, in Ecuador, significant clonal and AMR gene sharing of third generation cephalosporin resistant *E. coli*

was observed between children and animals, suggesting interlinkage of AMR in animals and humans¹⁶. The degree of sharing of bacteria strains and AMR determinants between different ecological compartments reported in studies such as these is certainly underestimated. This is particularly the case because carriage studies involving isolate WGS do not fully account for within sample diversity. Nevertheless, even without capturing that full diversity, the available evidence suggests exchange of AMR bacterial strains and AMR determinants between the different ecological compartments is common, particularly in low- and middle-income countries (LMICs).

WASH systems and the spread of AMR across ecological compartments

Detection of closely related ESBL-producing Enterobacteriaceae in humans, animals and the environment within LMICs not only illustrates the relevance of the One Health paradigm to key AMR human pathogens, but is also a manifestation of the poor environmental health standards and practices combined with the close interactions between humans, animals and the environment. Although not a surprise to the WASH community, the prominence of AMR as a global health issue can be used to shine new light on the urgency to address Sustainable Development Goal 6: ensuring the universal and equitable access to WASH for all. This could be effectively utilised to catalyse renewed enthusiasm and commitment for investment in WASH infrastructure, with aligned effective social and behaviour change programmes to reduce the interactions between these different ecological sources. On the other hand, the fact there is limited evidence for ESBL-*E. coli* and *K. pneumoniae* transmission between humans, animals and the environment in settings such as Europe where WASH infrastructure is strong, highlights the central role context appropriate approaches to improving environmental hygiene must play. The presence of these bacteria in healthcare settings informs us that IPC strategy in these settings is failing, placing patients at risk of adverse outcomes. Indeed, a high prevalence of healthcare associated infection, in part, illustrates a failure of environmental hygiene measures and practices in healthcare settings¹⁷. The response to AMR must not only be contextually appropriate, but also take a whole system approach, understanding that infection prevention is broader than the practice of IPC in healthcare facilities, and should embrace WASH infrastructure and practice in domestic, public and institutional settings. Indeed, to prevent severe bacterial infection from ESBL-*E. coli*, asymptomatic transmission of ESBL-enteric bacteria needs to be interrupted. AMR does not recognise the disciplinary silos in which we typically operate and the presence of widespread ESBL-enteric bacteria indicates that we are failing to create effective, equitable and sustainable access to basic WASH infrastructure and services for the most vulnerable populations in the world.

Conclusion

Evidence for a One Health Framework for AMR remains incomplete. While some studies have provided evidence of the need to take a One Health approach to AMR, such approaches will differ according to setting. Acknowledging however, that environments in LMIC are commonly contaminated by AMR bacteria such as ESBL-producing *E. coli* and *K. pneumoniae* and therefore unsafe, is a critical starting point. It demonstrates the need for a whole system approach to environmental hygiene, in which we will see catalytic and reinforcing advantages from transdisciplinary working to develop context appropriate and sustainable solutions that tackle global public health, economic

development, dignity and wellbeing simultaneously by improving WASH infrastructure and practice. Bacterial populations must be segregated by introducing transmission bottlenecks between human, animal and environmental compartments to reduce overall AMR transmission rates. To achieve this, there is an urgent need for designing, validating and understanding how best to implement such approaches in the face of competing public health priorities in all societies, and especially in LMICs.

Patrick Musicha ^{1,2}✉, Tracy Morse ³, Derek Cocker ^{1,4}, Lawrence Mugisha ⁵, Christopher P. Jewell⁶ & Nicholas A. Feasey ^{1,2,7}

¹Malawi Liverpool Wellcome Programme, Blantyre, Malawi. ²Liverpool School of Tropical Medicine, Liverpool, UK. ³University of Strathclyde, Glasgow, UK. ⁴University of Liverpool, Liverpool, UK. ⁵Makerere University, College of Veterinary Medicine, Animal Resources and Biosecurity, Kampala, Uganda. ⁶Lancaster University, Lancaster, UK. ⁷University of St. Andrews, St. Andrews, UK.

✉e-mail: pmusicha@mlw.mw

Received: 16 November 2023; Accepted: 26 September 2024;

Published online: 10 October 2024

References

- Robinson, T. P. et al. Antibiotic resistance is the quintessential One Health issue. *Trans. R. Soc. Trop. Med. Hyg.* **110**, 377–380 (2016).
- Day, M. J. et al. Extended-spectrum β -lactamase-producing *Escherichia coli* in human-derived and food chain-derived samples from England, Wales, and Scotland: an epidemiological surveillance and typing study. *Lancet Infect. Dis.* **19**, 1325–1335 (2019).
- Ludden, C. et al. One health genomic surveillance of *Escherichia coli* demonstrates distinct lineages and mobile genetic elements in isolates from humans versus livestock. *mBio* **10**, e02693–18 (2019).
- Thorpe, H. A. et al. A large-scale genomic snapshot of *Klebsiella* spp. isolates in Northern Italy reveals limited transmission between clinical and non-clinical settings. *Nat. Microbiol.* **7**, 2054–2067 (2022).
- Hanage, W. P. Two Health or Not Two Health? That Is the Question. *mBio* <https://doi.org/10.1128/mBio> (2019).
- Fuhrmeister, E. R. et al. Evaluating the relationship between community water and sanitation access and the global burden of antibiotic resistance: an ecological study. *Lancet Microbe* **4**, e591–e600 (2023).
- Cocker, D. et al. Drivers of Resistance in Uganda and Malawi (DRUM): a protocol for the evaluation of One-Health drivers of Extended Spectrum Beta Lactamase (ESBL) resistance in Low-Middle Income Countries (LMICs). *Wellcome Open Res.* **7**, 55 (2022).
- Cocker, D. et al. Investigating One Health risks for human colonisation with extended spectrum β -lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* in Malawian households: a longitudinal cohort study. *Lancet Microbe* **4**, e534–e543 (2023).
- Rimella, L. et al. Inference on extended-spectrum beta-lactamase *Escherichia coli* and *Klebsiella pneumoniae* data through SMC2. *J. R. Stat. Soc. C Appl. Stat.* <https://doi.org/10.1093/jrsssc/qlad055> (2023).
- Muloi, D. M. et al. Population genomics of *Escherichia coli* in livestock-keeping households across a rapidly developing urban landscape. *Nat. Microbiol.* **7**, 581–589 (2022).
- Hassell, J. M. et al. Epidemiological connectivity between humans and animals across an urban landscape. *Proc. Natl. Acad. Sci. USA* **120**, e2218860120 (2023).
- Muloi, D. M. et al. Genomic epidemiology of *Escherichia coli*: antimicrobial resistance through a One Health lens in sympatric humans, livestock and peri-domestic wildlife in Nairobi, Kenya. *BMC Med.* **20**, 471 (2022).
- Calland, J. K. et al. Population structure and antimicrobial resistance among *Klebsiella* isolates sampled from human, animal, and environmental sources in Ghana: a cross-sectional genomic One Health study. *Lancet Microbe* **4**, e943–e952 (2023).
- Musicha, P. et al. One Health in Eastern Africa: No barriers for ESBL producing *E. coli* transmission or independent antimicrobial resistance gene flow across ecological compartments. *bioRxiv* <https://doi.org/10.1101/2024.09.18.613694> (2024).
- Monteleone, M. C. et al. High Genomic Diversity and Heterogenous Origins Of Pathogenic And Antibiotic-resistant *Escherichia coli* in household settings represent a challenge to reducing transmission in low-income settings. *mSphere* **5**, e00704–e00719 (2020).
- Salinas, L. et al. Environmental spread of extended spectrum beta-lactamase (Esb) producing *Escherichia coli* and *esbl* genes among children and domestic animals in Ecuador. *Environ. Health Perspect.* **129**, 1–10 (2021).

17. Otter, J. A., Yezli, S., Salkeld, J. A. G. & French, G. L. Evidence that contaminated surfaces contribute to the transmission of hospital pathogens and an overview of strategies to address contaminated surfaces in hospital settings. *Am. J. Infect. Control* **41**, S6 (2013).

Author contributions

P.M. and N.A.F. conceived this work. P.M., T.M., C.P.J., and N.A.F. wrote the manuscript, with critical revision by D.C. and L.M. All the authors read and approved the final version of the manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Correspondence and requests for materials should be addressed to Patrick Musicha.

Peer review information *Nature Communications* thanks the anonymous reviewer(s) for their contribution to the peer review of this work.

Reprints and permissions information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

© The Author(s) 2024